Apr 04, 2018

Fagron Strengthens Strategic Position in USA Through Highly Complementary Acquisition of Humco

Fagron announces today the acquisition of Humco, a leading developer, manufacturer and supplier of patented delivery vehicles and branded pharmaceutical products to over 45,000 pharmacies in the USA. The acquisition price for Humco amounts to US$ 47.5 million (approximately € 38.6 million) in cash, with the potential for a performance linked earn-out of up to US$ 22.5 million (approximately € 18.3 million) in cash over a two-year period. The total consideration for the acquisition of Humco is thus capped at US$ 70.0 million (approximately € 56.9 million). The transaction includes all technologies, scientific data, patents and trademarks, as well as the production facility of Humco in Texas (USA).

Humco, founded in 1872 as Hutchison Medicine Company, realized a turnover of approximately US$ 32 million (approximately € 26 million) and an EBITDA-margin in line with that of the activities of Fagron North-America in 2017. The company is focused on developing, manufacturing and commercializing innovative patented delivery vehicles (including topical and transdermal creams, syrups and suspensions) and branded pharmaceutical products that are cash-paid by the customer (not reimbursed). In 2016, Humco added a limited portfolio of active pharmaceutical ingredients to its product offer. Humco serves over 45,000 pharmacies in the USA, mainly indirectly through pharmacy chains and wholesalers. Humco is located in Austin (Texas, USA) and has a state-of-the-art FDA registered, cGMP compliant production facility in Texarkana (Texas, USA). All 140 employees from Humco join Fagron, bringing expertise to innovate and serve an expanded customer base worldwide.

"I am pleased to welcome Humco to Fagron Group. Their high-quality portfolio of branded pharmaceutical products and widely used patented delivery vehicles that are supplied to a broad customer base of pharmacy chains and wholesalers in the USA is highly complementary to our extensive range of active pharmaceutical ingredients. Humco is an excellent strategic fit for Fagron. By combining the two companies, we create a strong competitive company with significant scale, strengthening our market position in the USA. Our global footprint and leading market positions in Europe and South-America will enable us to successfully launch and grow the innovative branded pharmaceutical products and delivery vehicles of Humco outside the USA. We look forward to welcome the Humco employees to the Fagron family," said Rafael Padilla, Fagron's CEO.

Following the transaction, Gregory Pulido, Humco's Chairman and CEO, will transition to the role of Executive Chairman while Andrew Pulido, Humco's current President, Global Pharmaceuticals, will assume the sole role of President at Humco.

"We are delighted and proud to become part of the Fagron Group. Being part of a large global organization and a world leader in pharmaceutical compounding creates a more capable and dynamic company for our customers and employees. We complement each other, selling in adjacent markets with very little customer overlap, enabling a significant number of growth opportunities. While we introduce our successful and unique patented delivery vehicles and branded pharmaceutical products internationally, our customers can benefit from the excellent range of more than 1,600 high quality active pharmaceutical ingredients of Fagron," said Gregory Pulido.

Andrew Pulido said, "I am honored to become Humco's President at such an exciting time. The joint activities of Fagron and Humco are extremely well positioned to capitalize on growth opportunities in the USA and around the world. I am confident that our expertise, creativity and dedication will enable us to offer increased value to our customers, suppliers and employees as well as to further extend Fagron's leadership in the market for personalized medication."

Market Buzz

Jun 15, 2018 Retail Management Solutions named in the top 250 of the Fifty Five and Five Inbo...
Jun 14, 2018 Tutela Welcomes Fertility Specialists Medical Group (FSMG) and The San Diego Cen...
Jun 11, 2018 SuiteRx Saves the day at APPA's 2nd Annual PharmaCon Expo
Jun 11, 2018 CPS Telepharmacy’s New Innovation Center Built to Meet Growing Technology Dema...
Jun 08, 2018 SuiteRx is Attending the 2nd Annual PharmaCon Expo in Orlando, Florida this week...
Jun 08, 2018 Worldwide Business with kathy ireland® Explores Infection Prevention with Analy...
Jun 04, 2018 FDS, Inc. Announces New CEO
May 25, 2018 Excelera Members Benefit from Accreditation Measure Validation Services Provided...
May 11, 2018 Sentara RMH Medical Center Partners with Omnicell to Enhance Efficiency, Safety ...
May 11, 2018 Medi-Dose, Inc. / EPS, Inc. Announces Auxiliary Labels for Neuromuscular Blockin...
May 09, 2018 Jamco First to Achieve Updated FM Approvals
May 03, 2018 CriticalPoint Peer Network
May 01, 2018 Contec, Inc. Acquires Building in Spartanburg County Industrial Park
May 01, 2018 SynMed® ULTRA now installed in the US
Apr 30, 2018 Diplomat Launches CastiaRx, Industry-Leading Specialty Benefit Manager
Apr 30, 2018 RXinsider is proud to present The Compliance Team as a Thought Leader in Exempla...
Apr 23, 2018 Lewis Drug Awarded Exemplary Provider® Accreditation
Apr 17, 2018 25% OFF Pharmacy Software License Fee
Apr 04, 2018 TCGRx Announces the Acquisition Of ARxIUM’S Panasonic Fastpak Exp and Fastpak ...
Apr 04, 2018 Fagron Strengthens Strategic Position in USA Through Highly Complementary Acquis...
Mar 30, 2018 KeyCentrix appoints Luis Rodriguez as President
Mar 27, 2018 iMedicare Rebrands to Amplicare, a Decision-Automation Platform that Enables Hea...
Mar 27, 2018 Mercyhealth Adopts Omnicell’s XR2 Automated Central Pharmacy System to Enhance...
Mar 26, 2018 Washington State University Wins 8th Annual Student Pharmacist Compounding Compe...
Mar 26, 2018 H+H SYSTEM, Inc. USA Appoints Marketing Manager
Mar 22, 2018 CVS Health Appoints Derica W. Rice as President of CVS Caremark
Mar 19, 2018 MEDISCA Signs Out-Licensing Agreement with Torrey Hills Technologies for its Pro...
Mar 16, 2018 QS/1® Achieves Level 2 Capability for the Pharmacist Electronic Care Plan
Mar 14, 2018 SuiteRx a Pharmacy Owner's Dream
Mar 13, 2018 Introducing Mission Critical Delivery Solutions as a Thought Leader in Long Term...

RXinsider Product Overview Videos